A study led by researchers from the Nanobioengineering Group at IBEC, in collaboration with other research centers and hospitals in Barcelona, uses a predictive biomarker to anticipate the success of drugs against rhabdomyosarcoma, which represents around 5 percent of childhood tumors . This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.
